Printer Friendly

Belgian UCB reports 19% Y/Y revenue growth in Q1 2015.

April 30 (SeeNews) - Belgian biopharmaceuticals firmA UCBA (EBR:UCB) said Thursday its revenue rose by 19% year-on-year to EUR 895 million (USD 1bn) in the first quarter of 2015 due to increased sales of its core medicines treating neurological or immunological diseases.

At constant currency rates, revenue growth was 11%.

Cimzia, Vimpat and Neupro generated combined net sales of EUR 433 million, while anti-epilepticA drugA Keppra reached EUR 190 million. The four drugs together represented 70% of UCB's revenue in the first quarter of 2015.A

UCB expects the continued growth of itsA blockbusters to drive overall company growth. Revenue in 2015 is expected to reach EUR 3.55 billion to EUR 3.65 billion, while recurring earnings before interest, tax, depreciation and amortisation (EBITDA) should increase to about EUR 710-740 million. Core earnings per share (EPS) are seen ranging from EUR 1.90 to EUR 2.05.

(EUR 1.0 = USD 1.110)

COPYRIGHT 2015 AII Data Processing Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:SeeNews Belgium
Article Type:Financial report
Date:Apr 30, 2015
Previous Article:State bank Belfius draws buyer interest - report.
Next Article:Belgian energy supplier Eandis looking for new partner - report.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters